148 related articles for article (PubMed ID: 20943848)
21. Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis.
Zhang L; Chen Y; Wang K
Curr Probl Cancer; 2019 Apr; 43(2):135-144. PubMed ID: 30017407
[TBL] [Abstract][Full Text] [Related]
22. Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study.
Feng LY; Liao SB; Li L
J Ovarian Res; 2020 Feb; 13(1):17. PubMed ID: 32050995
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the sensitivity and specificity of serum level of prostasin, CA125, LDH, AFP, and hCG+β in epithelial ovarian cancer patients.
Bastani A; Asghary A; Heidari MH; Karimi-Busheri F
Eur J Gynaecol Oncol; 2017; 38(3):418-424. PubMed ID: 29693884
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
[TBL] [Abstract][Full Text] [Related]
25. Increase of serum tumor marker concentrations by interferon-alpha.
Gebauer G; Jaeger W; Thiel G; Lang N
Eur J Gynaecol Oncol; 1998; 19(4):363-7. PubMed ID: 9744727
[TBL] [Abstract][Full Text] [Related]
26. An amplified comparative fluorescence resonance energy transfer immunosensing of CA125 tumor marker and ovarian cancer cells using green and economic carbon dots for bio-applications in labeling, imaging and sensing.
Hamd-Ghadareh S; Salimi A; Fathi F; Bahrami S
Biosens Bioelectron; 2017 Oct; 96():308-316. PubMed ID: 28525848
[TBL] [Abstract][Full Text] [Related]
27. Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.
Skates SJ; Greene MH; Buys SS; Mai PL; Brown P; Piedmonte M; Rodriguez G; Schorge JO; Sherman M; Daly MB; Rutherford T; Brewster WR; O'Malley DM; Partridge E; Boggess J; Drescher CW; Isaacs C; Berchuck A; Domchek S; Davidson SA; Edwards R; Elg SA; Wakeley K; Phillips KA; Armstrong D; Horowitz I; Fabian CJ; Walker J; Sluss PM; Welch W; Minasian L; Horick NK; Kasten CH; Nayfield S; Alberts D; Finkelstein DM; Lu KH
Clin Cancer Res; 2017 Jul; 23(14):3628-3637. PubMed ID: 28143870
[No Abstract] [Full Text] [Related]
28. Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1).
Schultes BC; Baum RP; Niesen A; Noujaim AA; Madiyalakan R
Cancer Immunol Immunother; 1998 Jun; 46(4):201-12. PubMed ID: 9671143
[TBL] [Abstract][Full Text] [Related]
29. The Use of Platelet/Lymphocyte Ratio and Cancer Antigen 125 Combined with Magnetic Resonance Diffusion-Weighted Imaging in Diagnosis of Recurrent Ovarian Cancer and Neuropathic Pain.
Wang N; Li C; Yang Y; Guan Y; Wang F; Wang Y; Zhao W
World Neurosurg; 2021 May; 149():502-510. PubMed ID: 33326856
[TBL] [Abstract][Full Text] [Related]
30. Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival-a substudy of the MIMOSA trial.
Buzzonetti A; Fossati M; Catzola V; Scambia G; Fattorossi A; Battaglia A
Cancer Immunol Immunother; 2014 Oct; 63(10):1037-45. PubMed ID: 24952307
[TBL] [Abstract][Full Text] [Related]
31. Monitoring of immune responses to CA125 with an IFN-gamma ELISPOT assay.
Schultes BC; Whiteside TL
J Immunol Methods; 2003 Aug; 279(1-2):1-15. PubMed ID: 12969543
[TBL] [Abstract][Full Text] [Related]
32. Combining a symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women with a pelvic mass.
Goff BA; Agnew K; Neradilek MB; Gray HJ; Liao JB; Urban RR
Gynecol Oncol; 2017 Nov; 147(2):291-295. PubMed ID: 28860006
[TBL] [Abstract][Full Text] [Related]
33. Microchip fluorescence-enhanced immunoaasay for simultaneous quantification of multiple tumor markers.
Shi M; Zhao S; Huang Y; Liu YM; Ye F
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Sep; 879(26):2840-4. PubMed ID: 21873123
[TBL] [Abstract][Full Text] [Related]
34. Anti-CA15.3 and Anti-CA125 Antibodies and Ovarian Cancer Risk: Results from the EPIC Cohort.
Cramer DW; Fichorova RN; Terry KL; Yamamoto H; Vitonis AF; Ardanaz E; Aune D; Boeing H; Brändstedt J; Boutron-Ruault MC; Chirlaque MD; Dorronsoro M; Dossus L; Duell EJ; Gram IT; Gunter M; Hansen L; Idahl A; Johnson T; Khaw KT; Krogh V; Kvaskoff M; Mattiello A; Matullo G; Merritt MA; Nodin B; Orfanos P; Onland-Moret NC; Palli D; Peppa E; Quirós JR; Sánchez-Perez MJ; Severi G; Tjønneland A; Travis RC; Trichopoulou A; Tumino R; Weiderpass E; Fortner RT; Kaaks R
Cancer Epidemiol Biomarkers Prev; 2018 Jul; 27(7):790-804. PubMed ID: 29661801
[No Abstract] [Full Text] [Related]
35. A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer.
Salminen L; Nadeem N; Jain S; Grènman S; Carpén O; Hietanen S; Oksa S; Lamminmäki U; Pettersson K; Gidwani K; Huhtinen K; Hynninen J
Gynecol Oncol; 2020 Mar; 156(3):689-694. PubMed ID: 31889528
[TBL] [Abstract][Full Text] [Related]
36. Comparison of Longitudinal CA125 Algorithms as a First-Line Screen for Ovarian Cancer in the General Population.
Blyuss O; Burnell M; Ryan A; Gentry-Maharaj A; Mariño IP; Kalsi J; Manchanda R; Timms JF; Parmar M; Skates SJ; Jacobs I; Zaikin A; Menon U
Clin Cancer Res; 2018 Oct; 24(19):4726-4733. PubMed ID: 30084833
[No Abstract] [Full Text] [Related]
37. Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study.
Guo N; Peng Z
J Ovarian Res; 2017 Mar; 10(1):14. PubMed ID: 28284216
[TBL] [Abstract][Full Text] [Related]
38. Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer.
Furrer D; Grégoire J; Turcotte S; Plante M; Bachvarov D; Trudel D; Têtu B; Douville P; Bairati I
PLoS One; 2019; 14(6):e0218621. PubMed ID: 31220149
[TBL] [Abstract][Full Text] [Related]
39. Distribution of radiolabelled anti-CA125 monoclonal antibody OC125-F(ab)2-fragment following resection guided by antibodies (REGAJ) in ovarian cancer patients.
Uttenreuther-Fischer MM; Feistel H; Wolf F; Jäger W
J Clin Lab Anal; 1997; 11(2):94-103. PubMed ID: 9058243
[TBL] [Abstract][Full Text] [Related]
40. Europium Nanoparticle-Based Sialyl-Tn Monoclonal Antibody Discriminates Epithelial Ovarian Cancer-Associated CA125 from Benign Sources.
Gidwani K; Nadeem N; Huhtinen K; Kekki H; Heinosalo T; Hynninen J; Perheentupa A; Poutanen M; Carpen O; Pettersson K; Lamminmäki U
J Appl Lab Med; 2019 Nov; 4(3):299-310. PubMed ID: 31659068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
